Full Product Name
LDB3 Antibody
Product Synonym Names
CYPHER; FLJ35865; KIAA01613; KIAA0613; ORACLE; PDLIM6; ZASP; ldb3z1; ldb3z4
Product Gene Name
anti-LDB3 antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Species Reactivity
Human, Mouse, Rat
Purity/Purification
Antigen affinity purification
Immunogen
Fusion protein of LDB3
Calculated Molecular Weight: 32/78kd
Observed Molecular Weight: 32kd; 78-80kd
Buffer
PBS with 0.1% sodium azide and 50% glycerol pH 7.3.
Santa Cruz Alternative
Potential replacement for Santa Cruz Biotechnology antibody catalog# sc-82848 / sc-98653
Preparation and Storage
Store at -20 degree C. Avoid freeze / thaw cycles
ISO Certification
Manufactured in an ISO 9001:2015 Certified Laboratory.
Other Notes
Small volumes of anti-LDB3 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Applications Tested/Suitable for anti-LDB3 antibody
ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC)
Application Notes for anti-LDB3 antibody
WB: 1:500-1:5000
IHC: 1:20-1:200
Testing Data of anti-LDB3 antibody
NCBI/Uniprot data below describe general gene information for LDB3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001165082.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001171611.1
[Other Products]
UniProt Secondary Accession #
Q5K6N9; Q5K6P0; Q5K6P1; Q96FH2; Q9Y4Z3; Q9Y4Z4; Q9Y4Z5; A2TDB7; A6NIV4; B4E3K3[Other Products]
UniProt Related Accession #
O75112[Other Products]
Molecular Weight
78,504 Da
NCBI Official Full Name
LIM domain-binding protein 3 isoform 6
NCBI Official Synonym Full Names
LIM domain binding 3
NCBI Official Symbol
LDB3 [Similar Products]
NCBI Official Synonym Symbols
MFM4; ZASP; CMD1C; CMPD3; LVNC3; CYPHER; LDB3Z1; LDB3Z4; ORACLE; PDLIM6
[Similar Products]
NCBI Protein Information
LIM domain-binding protein 3; LDB3; PDZ and LIM domain 6; Z-band alternatively spliced PDZ motif protein; Z-band alternatively spliced PDZ-motif protein; cardiomyopathy, dilated 1C (autosomal dominant); protein cypher
UniProt Protein Name
LIM domain-binding protein 3
UniProt Synonym Protein Names
Protein cypher; Z-band alternatively spliced PDZ-motif protein
Protein Family
LIM domain-binding protein
UniProt Gene Name
LDB3 [Similar Products]
UniProt Entry Name
LDB3_HUMAN
NCBI Summary for LDB3
This gene encodes a PDZ domain-containing protein. PDZ motifs are modular protein-protein interaction domains consisting of 80-120 amino acid residues. PDZ domain-containing proteins interact with each other in cytoskeletal assembly or with other proteins involved in targeting and clustering of membrane proteins. The protein encoded by this gene interacts with alpha-actinin-2 through its N-terminal PDZ domain and with protein kinase C via its C-terminal LIM domains. The LIM domain is a cysteine-rich motif defined by 50-60 amino acids containing two zinc-binding modules. This protein also interacts with all three members of the myozenin family. Mutations in this gene have been associated with myofibrillar myopathy and dilated cardiomyopathy. Alternatively spliced transcript variants encoding different isoforms have been identified; all isoforms have N-terminal PDZ domains while only longer isoforms (1, 2 and 5) have C-terminal LIM domains. [provided by RefSeq, Jan 2010]
UniProt Comments for LDB3
LDB3: May function as an adapter in striated muscle to couple protein kinase C-mediated signaling via its LIM domains to the cytoskeleton. Defects in LDB3 are the cause of cardiomyopathy dilated type 1C (CMD1C). Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. Defects in LDB3 are the cause of left ventricular non- compaction type 3 (LVNC3). Left ventricular non- compaction is characterized by numerous prominent trabeculations and deep intertrabecular recesses in hypertrophied and hypokinetic segments of the left ventricle. Defects in LDB3 are the cause of myopathy myofibrillar type 4 (MFM4). A neuromuscular disorder characterized by distal and proximal muscle weakness with signs of cardiomyopathy and neuropathy. 7 isoforms of the human protein are produced by alternative splicing.
Protein type: Cytoskeletal
Chromosomal Location of Human Ortholog: 10q22.3-q23.2
Cellular Component: cytoskeleton; perinuclear region of cytoplasm; pseudopodium; Z disc
Molecular Function: protein binding; protein kinase C binding; zinc ion binding; cytoskeletal protein binding; muscle alpha-actinin binding
Biological Process: sarcomere organization
Disease: Myopathy, Myofibrillar, 4
Research Articles on LDB3
1. results show that MFM-associated ZASP mutations in the actin-binding domain have deleterious effects on the core structure of the Z-discs in skeletal muscle.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
